Lyme Vaccine Advances in Late Trial - Takeaways - MDSpire

Lyme Vaccine Advances in Late Trial

Large global study evaluates novel prevention strategy.

  • By

  • Kathryn Wighton

  • March 23, 2026

  • 2 min

Share

  • 1

    The investigational Lyme disease vaccine PF-07307405 showed over 70% efficacy in a phase 3 trial.

  • 2

    Topline results indicated a 73% reduction in confirmed Lyme disease cases after the fourth dose.

  • 3

    The VALOR trial was a multicenter, randomized, placebo-controlled study conducted in high-incidence regions.

  • 4

    PF-07307405 targets outer surface protein A of Borrelia burgdorferi and aims to inhibit bacterial migration.

  • 5

    The vaccine was well tolerated with no safety concerns reported, addressing a significant public health issue.

Original Source(s)

Lyme Vaccine Advances in Late Trial

  • by Kathryn Wighton

  • March 23, 2026

Related Content

Recent COVID-19 Shot Linked to Less Spread

Protection against spread appeared strongest within 6 months of vaccination, while exposed vaccinated contacts showed no measurable reduction in infection risk.

RFK Jr. Takes Health Agenda on the Road

Touring Ohio, RFK Jr. highlights food quality and recovery services while steering attention away from vaccine controversies.

Prevalence, risk factors, and perceptions of vaccination against reproductive tract infections among urban females in Delhi: a cross-sectional study